Extending Technology Applications on a Wider Range of Cancers
We are also developing cancer diagnostics kits for test screening prostate, skin and cervical cancer risks using urine exfoliated cells, skin biopsies and PAP smear specimens. Additionally, we are extending our epigenetic imprinting platform towards fine needle aspirates and presurgical biopsy specimens for detecting breast, colorectal, esophageal, gastric, pancreatic, lymphatic, prostate, skin and cervical cancers.